Drugs / 18F-FLT

Trials 28 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 05 trials
Phase 0 NCT07609225 Jul 2026 → Jul 2029 expected castration-resistant prostate carcinoma University of Wisconsin, Madison Not yet recruiting No outcome recorded
Phase 0 NCT03613259 Jun 2020 → Jun 2022 soft tissue sarcoma OHSU Knight Cancer Institute Withdrawn No outcome recorded
Phase 0 NCT03422731 Feb 2018 → Nov 2026 expected acute lymphoblastic leukemia, acute myeloid leukemia City of Hope Medical Center Active not recruiting No outcome recorded
Phase 0 NCT03546556 Jan 2017 → Mar 2020 graft versus host disease UNC Lineberger Comprehensive Cancer Center Terminated No outcome recorded
Phase 0 NCT01825902 Mar 2013 → Jan 2014 Ewing sarcoma of bone, extraskeletal Ewing sarcoma, supratentorial primitive neuroectodermal tumor Mayo Clinic Completed No outcome recorded
Phase 15 trials
Phase 1 NCT02891616 Oct 2016 → Dec 2017 melanoma Washington University School of Medicine Terminated No outcome recorded
Phase 1 NCT00813566 Nov 2010 → Feb 2015 brain neoplasm, cancer University of Utah Completed No outcome recorded
Phase 1 NCT00880074 Apr 2009 → Feb 2022 cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT00633958 Mar 2008 → Mar 2010 central nervous system neoplasm Dana-Farber Cancer Institute Terminated No outcome recorded
Phase 1 NCT00553748 Nov 2007 → May 2008 brain cancer Siemens Molecular Imaging Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03276676 Sep 2018 → Apr 2021 brain neoplasm University of Utah Terminated No outcome recorded
Phase 210 trials
Phase 2 NCT03318497 Dec 2017 → Jun 2021 pancreatic adenocarcinoma University of Texas Southwestern Medical Center Completed No outcome recorded
Phase 2 NCT01717391 Oct 2012 → Feb 2016 anus neoplasm, endometrium neoplasm, prostate neoplasm, uterine cervix neoplasm John M. Buatti Completed No outcome recorded
Phase 2 NCT01610544 May → Dec 2012 non-small cell lung carcinoma, thymus neoplasm National Cancer Institute (NCI) Withdrawn No outcome recorded
Phase 2 NCT01480583 Oct 2011 → Jun 2015 breast cancer, metastatic malignant neoplasm in the brain Angiochem Inc Completed No outcome recorded
Phase 2 NCT01399658 Sep 2011 → Feb 2016 cervical cancer, vaginal cancer, vulvar carcinoma Dana-Farber Cancer Institute Completed No outcome recorded
Phase 2 NCT01338987 Apr 2011 → Dec 2017 acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT01244737 Oct 2010 → Feb 2023 brain neoplasm Frederick Daniel Grant Completed No outcome recorded
Phase 2 NCT01075412 Sep 2009 → Mar 2016 cervical cancer University of Iowa Terminated No outcome recorded
Phase 2 NCT00572728 Dec 2008 → Sep 2014 female breast carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00721799 Mar 2008 → Dec 2014 laryngeal neoplasm, neoplasm of oropharynx, oral cavity neoplasm University of Iowa Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00894101 May 2009 → Apr 2010 head and neck cancer University of California, Irvine Withdrawn No outcome recorded
Phase not applicable6 trials
NCT02241668 Jun 2015 brain neoplasm M.D. Anderson Cancer Center Withdrawn No outcome recorded
NCT01928186 Sep 2011 → Jul 2015 Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, male breast carcinoma University of Washington Completed No outcome recorded
NCT01243619 Aug 2010 → Mar 2013 esophageal cancer Dana-Farber Cancer Institute Completed No outcome recorded
NCT01713049 Aug 2010 → Dec 2012 breast neoplasm National Taiwan University Hospital Unknown No outcome recorded
NCT00979810 Sep 2009 → Feb 2020 brain cancer, glioma Memorial Sloan Kettering Cancer Center Completed No outcome recorded
NCT00847509 Feb 2009 → Aug 2010 head and neck cancer, lung cancer Siemens Molecular Imaging Completed No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 29 sources stand behind the page.

FieldValueCited text
Known as (18)F-FLT “Our objective was to determine whether early change in standardized uptake values (SUVs) of 3'deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) using PET with CT could predict...” PMID 26359256 Sep 2015
8

NCT03276676

NCT01338987

NCT00633958

NCT00572728

NCT01244737

NCT00979810

NCT01480583

NCT01713049

Known as 18F-fluorothymidine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02891616
1

NCT00721799

Known as 18Ffluoro-deoxy-L-thymidine “An imaging technique using a very small amount of a radioactive tracer called 18Ffluoro-deoxy-L-thymidine (18F-FLT) can detect areas of rapid growth within the tumor.” NCT00979810
Known as 3'-deoxy-3'-[F-18] fluorothymidine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03318497
Known as 3'deoxy-3'-(18)F-fluorothymidine “Our objective was to determine whether early change in standardized uptake values (SUVs) of 3'deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) using PET with CT could predict...” PMID 26359256 Sep 2015
6

NCT00813566

NCT01399658

NCT01610544

NCT07609225

NCT02241668

NCT01243619

Known as [F-18] Fluorothymidine [F-18] FluorothymidineNCT01717391
1

NCT01075412

Known as [F-18]FLT ClinicalTrials.gov intervention name — accepted as the source's own label NCT00847509
2

NCT00894101

NCT00553748

Known as FLT “3'-deoxy-3'-18F fluorothymidine (FLT)” NCT01610544
Known as fluorine F 18 fluorothymidine “Undergo fluorine F-18 fluorothymidine PET” NCT00880074
1

NCT01825902

Known as Fluorothymidine (FLT) ClinicalTrials.gov intervention name — accepted as the source's own label NCT03546556
Known as fluorothymidine F-18 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03422731
3

NCT03613259

NCT01717391

NCT01928186

Modality Diagnostic / imaging agent “PET imaging tracer” NCT00553748
Route Intravenous “administered IV” NCT00553748